Tuspetinib is a small molecule commercialized by Aptose Biosciences, with a leading Phase II program in Refractory Acute Myeloid Leukemia. According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Tuspetinib’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for Tuspetinib is expected to reach an annual total of $89 mn by 2034 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Tuspetinib Overview

Tuspetinib (HM-43239) is under development for the treatment of relapsed and refractory acute myeloid leukemia, relapsed/refractory high risk myelodysplastic syndrome (HR-MDS) and chronic myelomonocytic leukemia (CMML). The drug candidate is administered through oral route in the form of tablet. It acts by targeting FMS-like tyrosine kinase 3 (FLT3), spleen tyrosine kinase (SYK), Janus Kinase 1 and 2 (JAK1/2), tyrosine protein kinase c KIT, ribosomal protein S6 kinase (RSK2), TGF-beta-activated kinase 1 (MAP3K7/TAK1/TAB1).

Aptose Biosciences Overview

Aptose Biosciences (Aptose) is a clinical-stage biotechnology company that focuses on developing personalized therapies for the treatment of life-threatening cancers including, acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), certain B-cell malignancies, and other hematologic malignancies. The company’s cancer therapeutics pipeline products include HM43239, a myeloid kinome inhibitor (MKI), CG-806, a FLT3/BTK kinase inhibitor; APTO-253, a MYC oncogene inhibitor and APL-581, a dual BET Bromodomain-Kinase Inhibitor. Its small molecule cancer therapeutics pipeline product programs are designed to provide single agent benefit. It operates in Canada and the US and has collaborations with biopharmaceutical companies and healthcare centers for the development and commercialization of its pipeline product programs. Aptose is headquartered in San Diego, California, the US.

The operating loss of the company was US$42.6 million in FY2022, compared to an operating loss of US$65.5 million in FY2021. The net loss of the company was US$41.8 million in FY2022, compared to a net loss of US$65.4 million in FY2021.

For a complete picture of Tuspetinib’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 7 February 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.